| Company Name | Astellas Pharma |
|---|---|
| Protocol Number | HAURO-1201-TW |
| Title of Study | An open-label, prospective interventional study of the tolerability and efficacy of oral Harnalidge® OCAS®(Tamsulosin) 0.4 mg in patients who are unsatisfied with the treatment of Tamsulosin 0.2 mg |
| Primary Objective | To assess the tolerability and efficacy of Harnalidge® OCAS® 0.4 mg in Taiwan patients who are unsatisfied with tamsulosin 0.2 mg for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) |
| Number of Sites | 1 |
| Period of Study | From：01-Feb-2014 to：31-Dec-2014 |
| Number of Patients | 100人 |
| IRB Approval Date | 18-Sep-2013 |
| Publication Plan / Date | 2016 |
